|Bid||52.55 x 1000|
|Ask||60.08 x 1200|
|Day's Range||54.41 - 56.83|
|52 Week Range||21.08 - 86.03|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.83|
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
The first patient has been enrolled and randomized in Acerta Pharma’s ESCALADE trial, which is using Veracyte's LymphMark lymphoma subtyping test.
These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.